A gene therapy biotech helmed by an Alexion Pharmaceuticals co-founder has raised $40 million to develop a pipeline of drugs based on technology it licensed from Yale University.
Gennao Bio is developing drugs to treat cancer and rare monogenic skeletal muscle diseases using a cell-penetrating gene monoclonal antibody (GMAB) platform to deliver nucleic acids into cells.